CA2076975A1 - Vecteurs d'expression mammaliens - Google Patents

Vecteurs d'expression mammaliens

Info

Publication number: CA2076975A1
Authority: CA; Canada
Prior art keywords: plasmid; recombinant plasmid; cells; delimited; promoter
Prior art date: 1990-02-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2076975

Other languages

English (en)

Inventor

Kevin W. Moore

Paul J. Zavodny

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-02-28

Filing date

1991-02-26

Publication date

1991-08-29

1991-02-26 Application filed by Individual filed Critical Individual

1991-08-29 Publication of CA2076975A1 publication Critical patent/CA2076975A1/fr

Status Abandoned legal-status Critical Current

Links

239000013604 expression vector Substances 0.000 title description 3
239000013612 plasmid Substances 0.000 claims abstract description 146
108090000623 proteins and genes Proteins 0.000 claims abstract description 66
210000004962 mammalian cell Anatomy 0.000 claims abstract description 12
241000588724 Escherichia coli Species 0.000 claims abstract description 4
238000013518 transcription Methods 0.000 claims description 40
230000035897 transcription Effects 0.000 claims description 40
108010076504 Protein Sorting Signals Proteins 0.000 claims description 23
230000008488 polyadenylation Effects 0.000 claims description 21
108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
239000003623 enhancer Substances 0.000 claims description 13
230000010076 replication Effects 0.000 claims description 11
239000002299 complementary DNA Substances 0.000 claims description 10
101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 claims 4
102100024746 Dihydrofolate reductase Human genes 0.000 claims 2
108020001096 dihydrofolate reductase Proteins 0.000 claims 2
230000003612 virological effect Effects 0.000 claims 1
210000004027 cell Anatomy 0.000 abstract description 99
238000003780 insertion Methods 0.000 abstract description 7
230000037431 insertion Effects 0.000 abstract description 7
238000003776 cleavage reaction Methods 0.000 abstract description 6
230000007017 scission Effects 0.000 abstract description 6
230000002068 genetic effect Effects 0.000 abstract description 4
108010042407 Endonucleases Proteins 0.000 abstract description 2
102000004533 Endonucleases Human genes 0.000 abstract description 2
230000008929 regeneration Effects 0.000 abstract description 2
238000011069 regeneration method Methods 0.000 abstract description 2
230000037430 deletion Effects 0.000 abstract 1
238000012217 deletion Methods 0.000 abstract 1
108020004414 DNA Proteins 0.000 description 49
230000029087 digestion Effects 0.000 description 30
239000012634 fragment Substances 0.000 description 25
239000002609 medium Substances 0.000 description 20
108010022394 Threonine synthase Proteins 0.000 description 19
102000004419 dihydrofolate reductase Human genes 0.000 description 19
230000014509 gene expression Effects 0.000 description 13
238000000034 method Methods 0.000 description 13
101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 10
108091003079 Bovine Serum Albumin Proteins 0.000 description 9
102000055228 human IL5 Human genes 0.000 description 9
238000004166 bioassay Methods 0.000 description 8
239000003636 conditioned culture medium Substances 0.000 description 8
239000012091 fetal bovine serum Substances 0.000 description 8
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
239000013598 vector Substances 0.000 description 8
101150074155 DHFR gene Proteins 0.000 description 7
108010002616 Interleukin-5 Proteins 0.000 description 7
102000000743 Interleukin-5 Human genes 0.000 description 7
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
241000700605 Viruses Species 0.000 description 7
238000010276 construction Methods 0.000 description 7
229940100602 interleukin-5 Drugs 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
229960000485 methotrexate Drugs 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 6
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
239000013613 expression plasmid Substances 0.000 description 6
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 5
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
229960003677 chloroquine Drugs 0.000 description 5
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
230000010474 transient expression Effects 0.000 description 5
102000004594 DNA Polymerase I Human genes 0.000 description 4
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
229910000389 calcium phosphate Inorganic materials 0.000 description 4
239000001506 calcium phosphate Substances 0.000 description 4
235000011010 calcium phosphates Nutrition 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000003550 marker Substances 0.000 description 4
238000003199 nucleic acid amplification method Methods 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
108091008146 restriction endonucleases Proteins 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
229940104230 thymidine Drugs 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
238000011144 upstream manufacturing Methods 0.000 description 4
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
108010017826 DNA Polymerase I Proteins 0.000 description 3
229920002307 Dextran Polymers 0.000 description 3
101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
239000012980 RPMI-1640 medium Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
238000013459 approach Methods 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000004520 electroporation Methods 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
239000011543 agarose gel Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000007429 general method Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000003153 stable transfection Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
101150072531 10 gene Proteins 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000701822 Bovine papillomavirus Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010076804 DNA Restriction Enzymes Proteins 0.000 description 1
230000007023 DNA restriction-modification system Effects 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
101100496858 Mus musculus Colec12 gene Proteins 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710135464 Outer capsid protein sigma-3 Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
101710185500 Small t antigen Proteins 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
230000027455 binding Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
101150055766 cat gene Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000037516 chromosome inversion disease Diseases 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000006825 purine synthesis Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA 2076975 1990-02-28 1991-02-26 Vecteurs d'expression mammaliens Abandoned CA2076975A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48657190A	1990-02-28	1990-02-28
US486,571		1990-02-28

Publications (1)

Publication Number	Publication Date
CA2076975A1 true CA2076975A1 (fr)	1991-08-29

Family

ID=23932407

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2076975 Abandoned CA2076975A1 (fr)	1990-02-28	1991-02-26	Vecteurs d'expression mammaliens

Country Status (5)

Country	Link
EP (1)	EP0517768A1 (fr)
JP (1)	JPH05503015A (fr)
AU (1)	AU7444191A (fr)
CA (1)	CA2076975A1 (fr)
WO (1)	WO1991013160A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06502644A (ja) *	1990-11-16	1994-03-24	シェリング・コーポレーション	インターロイキン５による単球および好中球の増加および活性化法および骨髄細胞の成熟誘導法
EP0732404A4 (fr) *	1993-12-03	1997-07-30	Asahi Chemical Ind	Nouveau vecteur de detection d'expression
US5741657A (en)	1995-03-20	1998-04-21	The Regents Of The University Of California	Fluorogenic substrates for β-lactamase and methods of use
EP1143006B1 (fr) *	1996-08-19	2008-04-02	MorphoSys IP GmbH	Vecteurs/DNA-séquences provenant de banques d'anticorps humaines
EP2316951A1 (fr)	2001-01-17	2011-05-04	Trubion Pharmaceuticals, Inc.	Proteines de fusion d'immunoglobuline de domaine de liaison
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
ZA200506196B (en) *	2003-02-03	2006-10-25	Japan Immuno Inc	High-expression vector for animal cells
ATE514783T1 (de)	2003-11-12	2011-07-15	Schering Corp	Plasmidsystem zur expression mehrerer gene
AR046639A1 (es)	2003-11-21	2005-12-14	Schering Corp	Combinaciones terapeuticas de anticuerpo anti- igfr1
JP5164167B2 (ja)	2005-08-30	2013-03-13	ユニバーシティーオブマイアミ	免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
DK2170384T3 (en)	2007-07-02	2016-07-25	Etubics Corp	METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
WO2010062697A2 (fr)	2008-10-30	2010-06-03	Peixuan Guo	Biocapteur à connecteur de protéine motrice d'encapsulation d'adn viral à intégration membranaire pour séquençage d'adn et autres utilisations
US8137933B2 (en)	2008-11-12	2012-03-20	Schering Corporation	Mammalian expression vector pUHAB
EP2462165B1 (fr)	2009-08-03	2016-05-11	University of Miami	Méthode de prolifération in vivo de cellules t régulatrices
WO2014031178A1 (fr)	2012-08-24	2014-02-27	Etubics Corporation	Vecteur adénoviral à réplication déficiente, utile en vaccination
WO2014110258A1 (fr)	2013-01-09	2014-07-17	Podack Eckhard R	Compositions et procédés pour la régulation de lymphocytes t régulateurs à l'aide d'une protéine d'une fusion tl1a-ig

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4656134A (en) *	1982-01-11	1987-04-07	Board Of Trustees Of Leland Stanford Jr. University	Gene amplification in eukaryotic cells
GB8629153D0 (en) *	1986-12-05	1987-01-14	Ciba Geigy Ag	Hybrid proteins
DE3702116A1 (de) *	1987-01-24	1988-08-04	Behringwerke Ag	Kassetten-vektor-system zur expression offener leserahmen in eukaryotischen zellen

1991
- 1991-02-26 WO PCT/US1991/001078 patent/WO1991013160A1/fr not_active Application Discontinuation
- 1991-02-26 EP EP19910905143 patent/EP0517768A1/fr not_active Withdrawn
- 1991-02-26 JP JP50523791A patent/JPH05503015A/ja active Pending
- 1991-02-26 AU AU74441/91A patent/AU7444191A/en not_active Abandoned
- 1991-02-26 CA CA 2076975 patent/CA2076975A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
EP0517768A1 (fr)	1992-12-16
AU7444191A (en)	1991-09-18
JPH05503015A (ja)	1993-05-27
WO1991013160A1 (fr)	1991-09-05

Publication	Publication Date	Title
CA2045175C (fr)	2003-03-18	Production de proteines au moyen de la recombinaison homologue
CA1301675C (fr)	1992-05-26	Construction d'un vecteur d'expression polycistronique
CA2076975A1 (fr)	1991-08-29	Vecteurs d'expression mammaliens
CA1300533C (fr)	1992-05-12	Elements de regulation des sterols
Hitoshi et al.	1991	Efficient selection for high-expression transfectants with a novel eukaryotic vector
EP0173552B1 (fr)	1991-10-09	Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
EP0068740B1 (fr)	1989-03-22	Vecteurs de clonage d'ADN recombinant et transformants eucaryotiques et procaryotiques de ceux-ci
CA2071543C (fr)	2005-02-22	Methode de production de l'adn recombinant et vecteurs utilises pour cette production
US4965196A (en)	1990-10-23	Polycistronic expression vector construction
EP0724639A1 (fr)	1996-08-07	Procedes pour la selection de cellules hotes de recombinaison exprimant des niveaux eleves d'une proteine desiree
US5378603A (en)	1995-01-03	Method and composition for identifying substances which activate transcription of the LDL receptor gene
Reddy et al.	1982	Nonselective expression of simian virus 40 large tumor antigen fragments in mouse cells.
JP2001511342A (ja)	2001-08-14	内因性遺伝子の活性化によるヒト蛋白質の生産のためのヒト細胞株の同定
CA1310601C (fr)	1992-11-24	Vecteurs d'expression
EP0281246A2 (fr)	1988-09-07	Procédé pour améliorer l'amplification et l'expression de gènes étrangers
WO1988000975A1 (fr)	1988-02-11	Expression de genes heterologues pouvant etre induite a un haut niveau
WO1987005935A1 (fr)	1987-10-08	Procedes et compositions d'expression de produits genetiques eucaryotiques competitifs
AU602664B2 (en)	1990-10-25	DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
KR20010022126A (ko)	2001-03-15	내인성 유전자 활성화에 의해 사람 단백질을 생성시키는사람 세포계를 확인하는 방법
EA010059B1 (ru)	2008-06-30	Flp-опосредованная рекомбинация
JP2826114B2 (ja)	1998-11-18	遺伝子産物の製法
Harwood et al.	1990	Construction of a neo fusion gene for expression in both prokaryotic and eukaryotic cells
US20040265860A1 (en)	2004-12-30	Production of proteins using homologous recombination
NO845186L (no)	1986-06-23	Vektorsystem for innfoering av heterolog dna i eykaryotiske celler.

Legal Events

Date	Code	Title	Description
1994-08-27	FZDE	Dead